Promotion of Hepatocellular Carcinoma by the Intestinal Microbiota and TLR4

Cited by (1,000)

Items 801–900 of 1,000

1. Recent Advances in Practical Methods for Liver Cell Biology: A Short Overview
   Sandra Torres, Zeinab Abdullah, Maximilian Joseph Brol, Claus Hellerbrand, Mercedes Fernández, Romina Fiorotto, Sabine Klein, Philipp Königshofer, Christian Liedtke, Sophie Lotersztajn et al. · 2020 · International Journal of Molecular Sciences
2. Classical and Deep Learning Paradigms for Detection and Validation of Key Genes of Risky Outcomes of HCV
   Nagwan M. Abdel Samee · 2020 · Algorithms
3. Microbiota and cancer: In vitro and in vivo models to evaluate nanomedicines
   Abdallah Ladaycia, Brigitta Loretz, Catherine Passirani, Claus‐Michael Lehr, Élise Lepeltier · 2020 · Advanced Drug Delivery Reviews
4. A review of alcohol–pathogen interactions: New insights into combined disease pathomechanisms
   Natalia A. Osna, Moses New‐Aaron, Raghubendra Singh Dagur, Paul G. Thomes, Liz Simon, Danielle Evé Levitt, Patrick M. McTernan, Patricia E. Molina, Hye Yeon Choi, Keigo Machida et al. · 2022 · Alcoholism Clinical and Experimental Research
5. Gut dysbiosis in cutaneous T‐cell lymphoma is characterized by shifts in relative abundances of specific bacterial taxa and decreased diversity in more advanced disease
   Madeline J. Hooper, Tessa M. LeWitt, Yanzhen Pang, Francesca L. Veon, George Edward Chlipala, Leo Feferman, S.J. Green, Dagmar Sweeney, Katherine Bagnowski, Michael B. Burns et al. · 2022 · Journal of the European Academy of Dermatology and Venereology
6. Chronic Inflammatory and Immune Microenvironment Promote Hepatocellular Carcinoma Evolution
   Shimin Chen, Long Zhang, Yukun Chen, Xuzhi Zhang, Yi Ma · 2023 · Journal of Inflammation Research
7. Physiological mechanisms of TLR4 in glucolipid metabolism regulation: Potential use in metabolic syndrome prevention
   Feng Zeng, Jiawei Zheng, Li Shen, Daniela D. Herrera‐Balandrano, Wuyang Huang, Zhongquan Sui · 2022 · Nutrition Metabolism and Cardiovascular Diseases
8. Intestinal microbiota: A bridge between intermittent fasting and tumors
   Jing Liu, Nan Shao, Hui Qiu, Juanjuan Zhao, Chao Chen, Jiajia Wan, Zhixu He, Xu Zhao, Lin Xu · 2023 · Biomedicine & Pharmacotherapy
9. Mechanism-guided fine-tuned microbiome potentiates anti-tumor immunity in HCC
   Tao Liu, Ya Guo, Yanxia Liao, Jinping Liu · 2023 · Frontiers in Immunology
10. Emerging insights into the gut microbiota as a key regulator of immunity and response to immunotherapy in hepatocellular carcinoma
    Siqi Ren, Yinping Zhang, Xingyue Wang, Jiahong Su, Xiang Wang, Zijun Yuan, Xinyu He, Sipeng Guo, Yu Chen, Shuai Deng et al. · 2025 · Frontiers in Immunology
11. Microbiota in digestive cancers: our new partner?
    Anthony Lopez, Franck Hansmannel, Tunay Kökten, Jean–Pierre Bronowicki, Hassan Melhem, Harry Sokol, Laurent Peyrin‐Biroulet · 2017 · Carcinogenesis
12. Immunonutritional consequences of different serine-type protease inhibitors in a C57BL/6 hepatocarcinoma model
    José Moisés Laparra, Bartosz Fotschki, Claudia Mónika Haros · 2019 · Oncotarget
13. The two facets of gp130 signalling in liver tumorigenesis
    Dirk Schmidt‐Arras, Eithan Galun, Stefan Rose‐John · 2021 · Seminars in Immunopathology
14. Dysbiosis and liver diseases (Review)
    Hiroki Nishikawa, Shinya Fukunishi, Akira Asai, Keisuke Yokohama, Hideko Ohama, Shuhei Nishiguchi, Kazuhide Higuchi · 2021 · International Journal of Molecular Medicine
15. Host Microbiomes in Tumor Precision Medicine: How far are we?
    Federica D’Amico, Monica Barone, Teresa Tavella, Simone Rampelli, Patrizia Brigidi, Silvia Turroni · 2022 · Current Medicinal Chemistry
16. Disordered gut microbiota and changes in short-chain fatty acids and inflammatory processes in stress-vulnerable mice
    Wenjuan Han, Yaxin Zheng, Lan Wang, Cuixia An · 2023 · Journal of Neuroimmunology
17. HCC Is promoted by bacterial translocation and TLR-4 signaling: A new paradigm for chemoprevention and management
    Sara Toffanin, Helena Cornellà, Andrew Harrington, Josep Maria Llovet, Roberto J. Groszmann, Yasuko Iwakiri, Tamar Hamosh Taddei · 2012 · Hepatology
18. Classifying Aging As a Disease: The Role of Microbes
    Michael S. Lustgarten · 2016 · Frontiers in Genetics
19. Elevation of tumour markers TGF-β, M2-PK, OV-6 and AFP in hepatocellular carcinoma (HCC)-induced rats and their suppression by microalgae Chlorella vulgaris
    Khaizurin Tajul Arifin, Suhaniza Sulaiman, Suhana Saad, Hanafi Ahmad Damanhuri, Wan Zurinah Wan Ngah, Yasmin Anum Mohd Yusof · 2017 · BMC Cancer
20. Association between small intestinal bacterial overgrowth and toll-like receptor 4 in patients with pancreatic carcinoma and cholangiocarcinoma
    Xiaoying Ma, Heju Wang, Peng Zhang, Lin Xu, Zibin Tian · 2018 · The Turkish Journal of Gastroenterology
21. Microbiome-targeted nanoplatforms and engineering approaches in breast cancer therapy
    Zufa Sabeel, Yang Zhao · 2025 · Molecular Cancer
22. Role of Gut Microbiome in Oncogenesis and Oncotherapies
    Renuka Sri Sai Peddireddi, Sai Kiran Kuchana, Rohith Kode, Saketh Khammammettu, Aishwarya Koppanatham, Supriya Mattigiri, Harshavardhan Gobburi, Suresh K. Alahari · 2025 · Cancers
23. Polymorphism in the EREG gene confers susceptibility to tuberculosis
    Wen Cao, Liulin Luo, Weiwei Chen, Li Liang, Ranran Zhang, Yanlin Zhao, Jin Chen, Jun Yue · 2019 · BMC Medical Genetics
24. Nimbolide attenuates gut dysbiosis and prevents bacterial translocation by improving intestinal barrier integrity and ameliorating inflammation in hepatocellular carcinoma
    Amit Kumar Ram, Balasubramaniyan Vairappan, Bheemanathi Hanuman Srinivas · 2022 · Phytotherapy Research
25. Adamantane-linked isothiourea derivatives suppress the growth of experimental hepatocellular carcinoma via inhibition of TLR4-MyD88-NF-κB signaling.
    Hanan M. Hassan, Lamya Hamad Al-Wahaibi, George S.G. Shehatou, Ali Abdel-Rahman El-Emam · 2021 · PubMed Central
26. Lipid nanoparticle formulations for targeting leukocytes with therapeutic RNA in liver fibrosis
    Matthias Bartneck · 2021 · Advanced Drug Delivery Reviews
27. Tongue-coating microbiome as a cancer predictor: A scoping review
    Marwan Mansoor Ali Mohammed, Sausan Al Kawas, Gamilah Al‐Qadhi · 2021 · Archives of Oral Biology
28. Hepatocellular carcinoma and microbiota: Implications for clinical management and treatment
    Dario Spanu, Andrea Pretta, Eleonora Lai, Mara Persano, Clelia Donisi, Stefano Mariani, Marco Dubois, Marco Migliari, Giorgio Saba, Pina Ziranu et al. · 2022 · World Journal of Hepatology
29. Single Nucleotide Polymorphisms of Toll-like Receptor 4 in Hepatocellular Carcinoma—A Single-Center Study
    Θεόδωρος Ανδρουτσάκος, Athanasios‐Dimitrios Bakasis, Abraham Pouliakis, Maria Gazouli, Christos Vallilas, Gregorios S Hatzis · 2022 · International Journal of Molecular Sciences
30. C-reactive protein, a prognostic marker in hepatocellular carcinoma
    Jean‐François Dufour · 2013 · Hepatology
31. Invasive Salmonella Typhimurium colonizes gallbladder and contributes to gallbladder carcinogenesis through activation of host epigenetic modulator KDM6B
    Agila Kumari Pragasam, Sonalika Maurya, Kajal Jain, Sujoy Pal, Christu Raja, Rajni Yadav, Shakti Kumar, Ayushi Purohit, Dibyabhaba Pradhan, Kirti Kajal et al. · 2025 · Cancer Letters
32. A Gut Instinct on Leukaemia: A New Mechanistic Hypothesis for Microbiota-Immune Crosstalk in Disease Progression and Relapse
    Ilaria Stefania Pagani, Govinda Poudel, Hannah R. Wardill · 2022 · Microorganisms
33. Alkaloid from Alstonia yunnanensis diels root against gastrointestinal cancer: Acetoxytabernosine inhibits apoptosis in hepatocellular carcinoma cells
    Qi Lai, Chun‐Ju Yang, Qi zhang, Min Zhuang, Yan-Hua Ma, Chengyuan Lin, Guang‐Zhi Zeng, Jun-Lin Yin · 2023 · Frontiers in Pharmacology
34. Geranylgeranoic acid, a bioactive and endogenous fatty acid in mammals: a review
    Y. Shidoji · 2023 · Journal of Lipid Research
35. The Microbiome in Advanced Melanoma: Where Are We Now?
    Dylan D. Fortman, Drew E. Hurd, Diwakar Davar · 2023 · Current Oncology Reports
36. Early warning and diagnosis of liver cancer based on dynamic network biomarker and deep learning
    Yukun Han, Javed Akhtar, Guozhen Liu, Chenzhong Li, Guanyu Wang · 2023 · Computational and Structural Biotechnology Journal
37. Fecal microbial transplants as investigative tools in cancer
    Margaret Sue Bohm, Arvind V. Ramesh, Joseph F. Pierre, Katherine Loree Cook, E. Angela Murphy, Liza Makowski · 2024 · American Journal of Physiology-Gastrointestinal and Liver Physiology
38. Successful stories of drug repurposing for cancer therapy in hepatocellular carcinoma
    Yasmeen M. Attia, Heba A. Ewida, Mahmoud Salama Ahmed · 2020 · Elsevier eBooks
39. Clinical Aspects of Gut Microbiota in Hepatocellular Carcinoma Management
    Jinghang Xu, Qiao Zhan, Yanan Fan, Emily Kwun Kwan Lo, Fangfei Zhang, Yanyan Yu, Hani S El-Nezami, Zheng Zeng · 2021 · Pathogens
40. Inflammation and Hepatic Fibrosis, Then Hepatocellular Carcinoma
    Oh Sang Kwon, Seong Han Choi, Ju Hyun Kim · 2015 · Korean Journal of Gastroenterology
41. Hepatocyte Wnts Are Dispensable During Diethylnitrosamine and Carbon Tetrachloride-Induced Injury and Hepatocellular Cancer
    Morgan Preziosi, Minakshi Poddar, Sucha Singh, Satdarshan P. Monga · 2018 · Gene Expression
42. Gpr110 deficiency decelerates carcinogen-induced hepatocarcinogenesis via activation of the IL-6/STAT3 pathway.
    Benting Ma, Junjie Zhu, Juan Tan, Yulei Mao, Lingyun Tang, Chunling Shen, Hongxing Zhang, Ying Kuang, Jian Fei, Xiao Yi Yang et al. · 2017 · PubMed Central
43. Inhibition of proliferation and migration and induction of apoptosis in glioma cells by silencing TLR4 expression levels via RNA interference
    Yingzi Liu, Yingchao Ju, Jianghui Liu, Yuetong Chen, Xiangran Huo, Liang Liu · 2020 · Oncology Letters
44. Gut bacteria may control development of hepatocellular carcinoma
    Kazuto Tajiri, Yukihiro Shimizu · 2017 · HepatoBiliary Surgery and Nutrition
45. Nutraceuticals in the Modulation of the Intestinal Microbiota: Current Status and Future Directions
    Enzo Spisni, Silvia Turroni, Patrizia Alvisi, Renato Spigarelli, Demetrio Azzinnari, Dario Ayala, Veronica Imbesi, Maria Chiara Valerii · 2022 · Frontiers in Pharmacology
46. Nonalcoholic Fatty Liver Disease and the Intestinal Microbiome: An Inseparable Link
    Maria Effenberger, Christoph Grander, Felix Grabherr, Herbert Tilg · 2023 · Journal of Clinical and Translational Hepatology
47. Linking fatty liver diseases to hepatocellular carcinoma by hepatic stellate cells
    Liangen Chen, Xiang-Shi Ye, Lixian Yang, Jiang‐Sha Zhao, Jia You, Yuxiong Feng · 2024 · Journal of the National Cancer Center
48. Maternal obesity increases the risk of hepatocellular carcinoma through the transmission of an altered gut microbiome
    Beat Moeckli, Vaihere Delaune, Benoît Thomas P. Gilbert, Andrea Peloso, Graziano Oldani, Sofia El Hajji, Florence Slits, Joana Rodrigues Ribeiro, Ruben Mercier, Adrien Gleyzolle et al. · 2024 · JHEP Reports
49. Gut microbial dysbiosis in the pathogenesis of leukemia: an immune-based perspective
    Mayuri Goswami, Purabi Deka Bose · 2024 · Experimental Hematology
50. Manipulating the Gut Microbiome to Alleviate Steatotic Liver Disease: Current Progress and Challenges
    Ernesto Saenz, Nathally Espinosa Montagut, Baohong Wang, Christoph K. Stein-Thöringer, Kaicen Wang, Honglei Weng, Matthias P. Ebert, Kai Markus Schneider, Lanjuan Li, Andreas Teufel · 2024 · Engineering
51. Dysregulation in the microbiota by HBV and HCV infection induces an altered cytokine profile in the pathobiome of infection
    Marcos Daniel Mendes Padilha, Francisco Tiago de Vasconcelos Melo, Rogério Valois Laurentino, Andrea Nazaré Monteiro Rangel da Silva, Rosimar Neris Martins Feitosa · 2024 · The Brazilian Journal of Infectious Diseases
52. The multifaceted role of microbiota in liver cancer: pathogenesis, therapy, prognosis, and immunotherapy
    Yun Feng, Meng-Zhen Han, Yuhang Zhou, Yiwen Wang, Yue Wang, Tao Sun, Junnan Xu · 2025 · Frontiers in Immunology
53. Soluble epoxide hydrolase as a therapeutic target for obesity-induced disorders: roles of gut barrier function involved
    Jianan Zhang, Maolin Tu, Zhenhua Liu, Guodong Zhang · 2020 · Prostaglandins Leukotrienes and Essential Fatty Acids
54. Preventive strategy for nonalcoholic fatty liver disease-related hepatocellular carcinoma
    Yuri Cho, Bo Hyun Kim, Joong‐Won Park · 2022 · Clinical and Molecular Hepatology
55. Regulation of T Helper 17 by Bacteria: An Approach for the Treatment of Hepatocellular Carcinoma
    Cecilia Ying Ju Sung, Nikki Pui Yue Lee, Hani S El-Nezami · 2012 · International Journal of Hepatology
56. THE ROLE OF INNATE IMMUNITY FACTORS IN TUMORIGENESIS PROCESS
    О. А. Свитич, А. Б. Филина, N. V. Davydova, Ludmila V. Gankovskaya, Vitaly V. Zverev · 2018 · Medical Immunology (Russia)
57. MyD88-dependent signaling in non-parenchymal cells promotes liver carcinogenesis
    Antje Mohs, Nadine Kuttkat, Tobias Otto, Sameh A. Youssef, Alain de Bruin, Christian Trautwein · 2019 · Carcinogenesis
58. Innate and Adaptive Immunity Alterations in Metabolic Associated Fatty Liver Disease and Its Implication in COVID-19 Severity
    Patricia Lamadrid, M. Alonso-Peña, David San Segundo, M. Arias-Loste, J. Crespo, M. López-Hoyos · 2021 · Frontiers in Immunology
59. Coreopsis Tinctoria Modulates Lipid Metabolism by Decreasing Low-Density Lipoprotein and Improving Gut Microbiota
    Zhigang Ren, Yali Li, Jiangyun Liu, Haitao Li, Ang Li, Liangjie Hong, Guangying Cui, Ranran Sun, Muhuyati Wulasihan, Junhui Sun et al. · 2018 · Cellular Physiology and Biochemistry
60. Recent Advancements in Known and Emerging Risk Factors of Hepatocellular Carcinoma
    Muhammad Masroor Hussain, Feng Bi, Ju‐Mei Wang, Aoqiang Zhai, Fu‐Yu Li, Hai Hu · 2025 · Cancer Medicine
61. Using proton pump inhibitors increases the risk of hepato-biliary-pancreatic cancer. A systematic review and meta-analysis
    Wence Zhou, Xinlong Chen, Qigang Fan, Haichuan Yu, Wenkai Jiang · 2022 · Frontiers in Pharmacology
62. Urinary microbiome-based metagenomic signature for the noninvasive diagnosis of hepatocellular carcinoma
    Eun Ju Cho, Boram Kim, Su Jong Yu, Suk Kyun Hong, YoungRok Choi, Nam‐Joon Yi, Kwang‐Woong Lee, Kyung‐Suk Suh, Jung‐Hwan Yoon, Taesung Park · 2024 · British Journal of Cancer
63. Modulating the gut microbiome in non-small cell lung cancer: Challenges and opportunities
    Jii Bum Lee, Yiqing Huang, Yuko Oya, Jorn Nützinger, Yvonne L.E. Ang, Kenneth W.X. Sooi, Byoung Chul Cho, Ross Andrew Soo · 2024 · Lung Cancer
64. Role of Gut Microbiome in Cancer Treatment
    Vijay Mishra, Yachana Mishra · 2024 · Indian Journal of Microbiology
65. PPARα affects hepatic lipid homeostasis by perturbing necroptosis signals in the intestinal epithelium
    Shufang Na, Yanjie Fan, Honglei Chen, Ling Li, Guolin Li, Furong Zhang, Rong-Yan Wang, Yafei Yang, Zixia Shen, Zhuang Peng et al. · 2024 · Acta Pharmaceutica Sinica B
66. Exploring the effects of gut microbiota on cholangiocarcinoma progression by patient-derived organoids
    Ann‐Kathrin Lederer, Nele Görrissen, Tinh Thi Nguyen, Clemens Kreutz, Hannah Rasel, F. Bartsch, Hauke Lang, Kristina Endres · 2025 · Journal of Translational Medicine
67. Identification of intratumoral bacteria that enhance breast tumor metastasis
    Zachary J. Gerbec, Antonio Serapio-Palacios, Avril Metcalfe‐Roach, Zakhar Krekhno, Haggai Bar‐Yoseph, Sarah E. Woodward, Jorge Peña-Díaz, Oksana Nemirovsky, Shannon J. Awrey, Sebastian H. Moreno et al. · 2025 · mBio
68. Unveiling the potential of natural TLR modulators in cancer immunotherapy
    Wenying Zheng, Junming Chen, Jiajun Liu, Xintong Han, Siyuan Zhang, Chao Yang, Hua Yu, Wen Tan, Zhangfeng Zhong · 2025 · Pharmacological Research
69. The Role of the Gut Microbiome in Pathogenesis, Biology, and Treatment of Plasma Cell Dyscrasias
    Marcin Jasiński, Jarosław Biliński, Grzegorz Władysław Basak · 2021 · Frontiers in Oncology
70. Molecular alterations that precede the establishment of the hallmarks of cancer: An approach on the prevention of hepatocarcinogenesis
    Brisa Rodope Alarcón‐Sánchez, Julio Isael Pérez‐Carreón, Saúl Villa‐Treviño, Jaime Arellanes‐Robledo · 2021 · Biochemical Pharmacology
71. Roles of heterogenous hepatic macrophages in the progression of liver diseases
    Kyeongjin Lee, Mi‐Yeon Kim, Yong‐Hyun Han · 2022 · BMB Reports
72. Association of toll-like receptors single nucleotide polymorphisms with HBV and HCV infection: research status
    Yaxin Xu, Wentao Xue, Hongwei Gao, Jiabo Cui, Lingzhi Zhao, Chongge You · 2022 · PeerJ
73. The role of immune cells in the liver tumor microenvironment: an involvement of gut microbiota-derived factors
    Tomonori Kamiya, Naoko Ohtani · 2022 · International Immunology
74. Immunotherapy for nonalcoholic fatty liver disease-related hepatocellular carcinoma: Lights and shadows
    F. Costante, Carlo Airola, F. Santopaolo, A. Gasbarrini, M. Pompili, F. Ponziani · 2022 · World Journal of Gastrointestinal Oncology
75. Konjac glucomannan enhances 5-FU-induced cytotoxicity of hepatocellular carcinoma cells via TLR4/PERK/CHOP signaling to induce endoplasmic reticulum stress
    YONGKANG SHI, Jun Ma, KE CHEN, BIN CHEN · 2022 · Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics
76. Modulation of the Tumor Microenvironment by Ellagic Acid in Rat Model for Hepatocellular Carcinoma: A Potential Target against Hepatic Cancer Stem Cells
    Wafaa S. Ramadan, Saleh Alkarim, Mohammed Moulay, Ghadeer I. Alrefaei, Fatma Al-Qudsi, Khalid Rehman Hakeem, Ashwaq Iskander · 2023 · Cancers
77. Chronic liver inflammation and hepatocellular carcinogenesis are independent of S 100 A 9
    Aurora De Ponti, Lars Wiechert, Ana Stojanovic, Thomas Longerich, Silke Marhenke, Nancy Hogg, Arndt Vogel, Adelheid Cerwenka, Peter Schirmacher, Jochen Heß et al. · 2014 · International Journal of Cancer
78. Specific alterations in gut microbiota are associated with prognosis of Budd-Chiari syndrome
    Yu-Ling Sun, Wenqi Li, Peng‐Xu Ding, Zhi-Wei Wang, Changhua Wei, Xiu-Xian Ma, Ruifang Zhang, Yan Wu, Lin Zhou, Ruopeng Liang et al. · 2017 · Oncotarget
79. [Gut microbiota-an important contributor to liver diseases].
    Fangzhao Wang, Qianru Cui, Yunong Zeng, Chen Peng · 2020 · PubMed Central
80. Type I Interferon Signaling Accelerates Liver Regeneration by Metabolic Modulation in Noninfectious Conditions
    Ming-Sian Wu, Yi-Ping Kuo, Yin-Chiu Lo, De-Jiun Tsai, Chao-Yang Lai, Tsung‐Hsien Chuang, Shu‐Yi Lin, Wan-Ting Tsai, Pei‐Jung Chung, Guann‐Yi Yu · 2021 · American Journal Of Pathology
81. Gut microbiota and immune system in liver cancer: Promising therapeutic implication from development to treatment
    Ilenia Bartolini, Matteo Risaliti, Rosaria Tucci, Paolo Muiesan, Maria Novella Ringressi, Antonio Taddei, Amedeo Amedei · 2021 · World Journal of Gastrointestinal Oncology
82. Host–microbe cross talk in cancer therapy
    Barbara W.A. Vanhoecke, Andrea M. Stringer · 2015 · Current Opinion in Supportive and Palliative Care
83. Mechanism of neoagarotetraose protects against intense exercise-induced liver injury based on molecular ecological network analysis
    Xin Chen, Jiahong Yu, Changhu Xue, Yuming Wang, Qingjuan Tang, Xiangzhao Mao · 2019 · Bioscience Biotechnology and Biochemistry
84. Liver diseases: The pathogenetic role of the gut microbiome and the potential of treatment for its modulation
    К. А. Айтбаев, Ilkhom T. Murkamilov, Victor V. Fomin · 2017 · Terapevticheskii arkhiv
85. Common Denominator of MASLD and Some Non-Communicable Diseases
    Katarzyna Ferenc, Sara Jarmakiewicz-Czaja, Aneta Sokal-Dembowska, Katarzyna Stasik, Rafał Filip · 2024 · Current Issues in Molecular Biology
86. A high-fat diet induced depression-like phenotype via hypocretin-HCRTR1 mediated inflammation activation
    Jingyi Dong, Jinghui Zhang, Shangping Cheng, Bin Qin, Kangyu Jin, Bing Chen, Yuyan Zhang, Jing Lü · 2024 · Food & Function
87. Preventive effect of MitoQ supplementation and endurance training on glioblastoma and its consequences: TLR4/CREB/ NF-κβ /IL-1β pathway and behaviors
    Soheil Aminizadeh, Amirhossein Moslemizadeh, Sara Sheibani, Zahra Sedighi-Khovidak, Zahrasadat Roholamini, Saeideh Jafarinejad‐Farsangi, Reza Kheirandish, Vahid Sheibani, Hamideh Bashiri · 2024 · International Immunopharmacology
88. Intratumoral microbiota for hepatocellular carcinoma: from preclinical mechanisms to clinical cancer treatment
    Muhua Chen, Lei Bie · 2025 · Cancer Cell International
89. Understanding crosstalk between the gut and liver microbiome: pathogenesis to therapeutic approaches in liver cancer
    Himanshi Goyal, Kaneez Fatima, Jyotdeep Kaur · 2025 · Cancer Cell International
90. Microbiome dysbiosis and immune checkpoint inhibitors: Dual targets in Hepatocellular carcinoma management
    Kadek Mercu Narapati Pamungkas, Putu Itta Sandi Lesmana Dewi, Ajib Zaim Alamsyah, Ni Luh Putu Yunia Dewi, Ni Nyoman Gita Kharisma Dewi, I Ketut Mariadi, Dwijo Anargha Sindhughosa · 2025 · World Journal of Hepatology
91. IL ‐13 but not IL ‐4 signaling via IL ‐4Rα protects mice from papilloma formation during DMBA / TPA two‐step skin carcinogenesis
    Michael Rothe, David Quarcoo, Anna A. Chashchina, Svetlana V. Bozrova, Zhihai Qin, Sergei A. Nedospasov, Thomas J. F. Blankenstein, Thomas Kammertoens, Marina S. Drutskaya · 2013 · Cancer Medicine
92. Hepatocellular carcinoma in the context of non-alcoholic steatohepatitis (NASH): recent advances in the pathogenic mechanisms
    M. Lequoy, E. Gigante, J. Couty, C. Desbois-Mouthon · 2020 · Hormone Molecular Biology and Clinical Investigation
93. Predictive and Prognostic Roles of Gut Microbial Variation in Liver Transplant
    Hon Jen Wong, Wen Hui Lim, Cheng Han Ng, Darren Jun Hao Tan, Glenn Kunnath Bonney, Alfred Wei Chieh Kow, Daniel Q. Huang, Mohammad Shadab Siddiqui, Mazen Noureddin, Nicholas L. X. Syn et al. · 2022 · Frontiers in Medicine
94. Stenotrophomonas maltophilia promotes lung adenocarcinoma progression by upregulating histone deacetylase 5
    Jiyu Shen, Yalan Ni, Qijie Guan, Rui Li, Hong Cao, Yan Geng, Qingjun You · 2023 · Frontiers in Microbiology
95. Biomarkers of gut barrier dysfunction and risk of hepatocellular carcinoma in the REVEAL‐HBV and REVEAL‐HCV cohort studies
    Jessica L. Petrick, Andrea A. Florio, Jane Zen, Yanyu Wang, Andrew T. Gewirtz, Ruth M. Pfeiffer, Sarah A. Loftus, Jon R. Inglefield, Jill E. Koshiol, Baiyu Yang et al. · 2023 · International Journal of Cancer
96. Mendelian randomization analysis to investigate the gut microbiome in oral and oropharyngeal cancer
    Qihe Zhang, Huanhuan Wang, Yuan Tian, Jinjie Li, Ying Xin, Xin Mei Jiang · 2024 · Frontiers in Cellular and Infection Microbiology
97. Gut microbiota and Toll-like receptors set the stage for cytokine-mediated failure of antibacterial responses in the fibrotic liver
    Christian Kuntzen, Robert F. Schwabe · 2016 · Gut
98. When Soluble Fibers Meet Hepatocellular Carcinoma: The Dark Side of Fermentation
    Suchira Gallage, Elena Kotsiliti, Mathias F Heikenwälder · 2018 · Cell Metabolism
99. The microbiome, its molecular mechanisms and its potential as a therapeutic strategy against colorectal carcinogenesis (Review)
    Stella Baliou, Maria Adamaki, Demetrios A. Spandidos, Anthony M. Kyriakopoulos, Ioannis Christodoulou, Vassilis C. Zoumpourlis · 2018 · World Academy of Sciences Journal
100. Plasma diamine oxidase level predicts 6-month readmission for patients with hepatitis B virus-related decompensated cirrhosis
     Feng-Cai Li, Yu‐Chen Fan, Yuekai Li, Kai Wang · 2019 · Virology Journal